Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Wyeth, Advanced Life In Pact To Develop Antibiotic For Southeast Asia

This article was originally published in PharmAsia News

Executive Summary

Wyeth is investing $100 million in a collaboration with Advanced Life Sciences, Holdings, also of the U.S., to develop and market a pneumonia antibiotic for the Asia Pacific region, but excluding Japan. Advanced Life licensed the cethromycin drug from Abbott Laboratories, which has applied for approval in the U.S. and Japan. The drug is one of a class of ketolide antibiotics prescribed to prevent infectious bacteria from becoming resistant to drugs. Advanced Life and Wyeth intend to develop the drug to treat community-acquired pneumonia. (Click here for more

You may also be interested in...

Wyeth Plans To Market Second-Generation Ketolide In Asia Pacific Region

HONG KONG - Wyeth plans to market a second-generation ketolide in the Asia Pacific region, noting that serious side effects associated with the first generation of the new type of antibiotic have not surfaced

Mylan Bids To Win EU Approval For Upjohn Merger

Mylan and Pfizer’s Upjohn, already facing a delay to their proposed merger, may have to overcome regulatory barriers to get the deal over the line.

IGBA Criticizes Export Restrictions

National export restrictions on medicines have been slammed by the international off-patent pharmaceutical industry as being “counter-productive” during the coronavirus crisis. The IGBA is instead urging international co-operation and transparency, pointing to a positive example of supply-chain connectivity in the Asia-Pacific region.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts